<DOC>
	<DOCNO>NCT00091481</DOCNO>
	<brief_summary>To show non-inferiority incidence rate elevate calcium-phosphorus product two treatment group : 1 ) group initial dose base baseline PTH ( baseline iPTH/80 ) 2 ) group start dose base body weight ( 0.04 mcg/kg ) .</brief_summary>
	<brief_title>Study Compare Initial Dosing Parameters Zemplar Stage V Chronic Kidney Disease Subjects Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Stage V Chronic Kidney Disease Patients Hemodialysis require treatment secondary hyperparathyroidism vitamin D therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Stage V Chronic Kidney Disease</keyword>
</DOC>